- Rating
- 1
- Confidence
- 4
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
This paper presents PODA (Privileged On-Policy Distillation for Antibody and Nanobody Design). This is a two-stage antibody sequence–structure flow framework. In Stage I, a public-input student and a privileged teacher are jointly supervised on the same complexes, yielding the resulting student model. In Stage II, the teacher is frozen while the student is updated on re-noised endpoints generated online by its evolving policy. The distillation process aligns the student with teacher-predicted clean endpoints, places emphasis on CDR and interface residues, and gates teacher targets according to reconstruction quality.
Critical strengths
-
The paper proposes a distillation method based on a flow network model for conditional antibody CDR design. Through a two-stage training process, the method successfully achieves the goal of antibody CDR generation.
-
Antibody design is a highly complex challenge in practical drug development. In this paper's experimental evaluation, the authors incorporate a broad range of validation metrics to assess performance as comprehensively as possible, which is a commendable approach.
Critical weaknesses
-
In terms of algorithmic innovation, the reconstruction objective used to train the flow model in the first stage is already widely adopted, while the distillation of information between two models with identical architectures in the second stage is also a well-established approach. Consequently, the paper offers limited technical novelty overall.
-
Regarding experimental evaluation, antibody CDR design is a well-established research topic with numerous relevant baseline methods based on GNNs, diffusion models, and flow-based models. The paper’s limited incorporation of baselines hinders a rigorous assessment of the proposed method’s advantages.
-
Importantly, the ultimate goal of AI-assisted antibody design is to advance candidates into real-world clinical drug development pipelines. Although this study does not include wet-lab experiments, it should provide sufficiently robust in silico validation to inform future experimental work. However, the scope of the evaluation remains limited: CDR segments typically contain only around 10 amino acids, and the test set comprises fewer than 100 antibodies. These limitations substantially constrain this study’s research value and potential impact.
Questions for authors
The authors should more clearly articulate this paper’s principal algorithmic contributions and expand the experimental evaluation to address its current limitations, thereby providing more meaningful insights for future research and practical applications.